Comparison of the efficacy of dapagliflozin and sitagliptin in the treatment of overweight patients with type 2 diabetes mellitus
WANG Xiaodong
NAN Feining
Abstract：Objective To compare the efficacy of dapagliflozin and sitagliptin in the treatment of overweight pa-tients with type 2 diabetes mellitus(T2DM).Methods A total of 122 T2DM patients with body mass index no less than 24.0 kg/m2 treated in Shangluo Central Hospital from January 2021 to December 2021 were enrolled in the study and di-vided into the group A with 63 cases and the group B with 59 cases according to the treatment method.The group A was treated with conventional intervention plus metformin and sitagliptin,while the group B was given conventional inter-vention plus metformin and dapagliflozin.Both groups were treated for 24 weeks.The body weight,blood pressure,gly-cometabolism indexes(fasting blood glucose,glycated haemoglobin,fasting insulin),serum uric acid(SUA),urinary albumin-to-creatinine ratio(UACR),lipid indexes(triglycerides(TG),total cholesterol(TC),low-density lipoprotein cholesterol,high-density lipoprotein cholesterol),serum adiponectin,tumor necrosis factor-α(TNF-α),pancreatic β-cell function indexes(early-phase insulin secretion index,area under the insulin curve)and incidence of adverse reactions were compared between the two groups before and after treatment.Results The body mass,systolic blood pressure and diastolic blood pressure of the group B were respectively(74.24±7.33)kg,(120.73±14.51)mmHg(1 mmHg=0.133 kPa)and(64.20±5.03)mmHg after treatment for 24 weeks,lower than(77.60±7.25)kg,(130.69±13.46)mmHg and(66.18±4.05)mmHg of the group A(t=2.545,3.933,2.402,all P＜0.05).The levels of TG,SUA and UACR of the group B were respectively(1.67±0.49)mmol/L,(422.72±38.03)μmo/L and(46.28±6.56)mg/g after treatment for 24 weeks,lower than(1.86±0.45)mmol/L,(449.73±52.02)μmo/L and(49.52±7.13)mg/g of the group A(t=2.233,3.265,2.607,all P＜0.05).The TNF-α level of the group B was(1.53±0.49)ng/L after treatment for 24 weeks,lower than(1.74±0.45)ng/L of the group A(t=2.468,P＜0.05),while the levels of adiponectin,early-phase insulin secretion index and area under the insulin curve of the group B were respectively(5.29±1.03)μg/mL,(4.78±0.90)mU/mmol and(102.45±16.59)U/mL·(180 min),higher than(4.64±1.19)μg/mL,(3.96±0.83)mU/mmol and(90.44±15.74)U/mL·(180 min)of the group A(t=3.216,5.235,4.103,all P＜0.05).The incidence of adverse reactions was 12.70%(8/63)in the group A and 16.95%(10/59)in the group B,with no statistically significant difference between the two groups(χ2=0.438,P=0.508).Conclusion Both dapagliflozin and sitagliptin provide ef-fective glycemic control with a favorable safety profile in the overweight patients with T2DM.Dapagliflozin has advantages in the control of body weight,blood pressure,and the reduction of TG,blood uric acid and UACR as well as the improvement of microinflammatory state and adipocyte function.
Keywords：dapagliflozinsitagliptintype 2 diabetes mellitusadiponectintumor necrosis factor-αpancreatic β-cell function
Publication Date：2025-12-25
Online Publishing Date：2026-01-07(First online date of this platform, not the publication date of the document)
Pages：5( 1512-1516 )